Welcome to Campus Sanofi Malaysia

Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.

DUPIXENT has demonstrated a consistent safety profile in adults with moderate-to- severe AD, supported by five years of clinical trial data and real-world evidence across all age groups from 6 months through adulthood.¹

Access ERS 2026 Congress highlights on severe asthma, COPD, and biologic therapies. Real-world evidence and clinical insights for HCPs

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

Missed this webinar? You can now watch the recording of the webinar to learn about the role of biologics in severe asthma and COPD¹ through real-world clinical cases presented by a panel of expert clinicians.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Missed the live session? You can now watch the Advanced Airways Collaborative webinar on-demand.​